Related Experiment Video
Updated: Jul 13, 2025
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Published on: June 28, 2013
The emerging role of PANoptosis in cancer treatment
1Department of Pharmaceutics, Key Laboratory of Basic Pharmacology of Guizhou Province, and School of Pharmacy, Zunyi Medical University, Zunyi, China; Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International, Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
Abstract:
Programmed cell death (PCD) is a key mechanism for the study of anticancer drugs and has a significant impact on the development and management of cancer. A growing amount of data indicates that different kinds of PCD, particularly pyroptosis, apoptosis, and necroptosis, interact closely. Recent research has revealed the existence of the distinct inflammatory PCD modality known as PANoptosis, which is controlled by complex PANoptosome complexes built by combining elements from different PCD pathways. No single PCD route is sufficient to explain all of the physiologic effects seen in PANoptosis. Numerous studies have demonstrated that PANoptosis can successfully stop cancer cells from growing, proliferating, and developing drug resistance. As a result, it has changed the focus of targeted anticancer therapy. In this review, we outlined the molecular processes of PANoptosis activation and modulation as well as the mechanisms of innate immune cell death. In order to provide a theoretical foundation for the development of drugs targeting PANoptosis as an anti-cancer target, we also highlight the PANoptosomes discovered to date and give an overview of the implications of PANoptosis in cancer treatment.
Insights
PANoptosis, a novel inflammatory cell death, combines elements of pyroptosis, apoptosis, and necroptosis. This programmed cell death pathway shows promise in halting cancer growth and overcoming drug resistance, offering new therapeutic targets.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Programmed cell death (PCD) is crucial for cancer drug development.
- Interactions between pyroptosis, apoptosis, and necroptosis are increasingly recognized.
- PANoptosis emerges as a distinct inflammatory PCD modality involving PANoptosome complexes.
Purpose of the Study:
- To review the molecular mechanisms of PANoptosis activation and modulation.
- To explore the role of PANoptosis in innate immune cell death.
- To discuss the therapeutic implications of targeting PANoptosis in cancer treatment.
Main Methods:
- Literature review of programmed cell death pathways.
- Analysis of molecular components and regulation of PANoptosis.
- Synthesis of current research on PANoptosis and cancer.
Main Results:
- PANoptosis integrates pathways like pyroptosis, apoptosis, and necroptosis.
- PANoptosis effectively inhibits cancer cell proliferation and drug resistance.
- PANoptosome complexes are key regulators of this inflammatory cell death.
Conclusions:
- PANoptosis represents a significant advance in understanding inflammatory cell death.
- Targeting PANoptosis offers a promising strategy for novel anti-cancer therapies.
- Further research into PANoptosomes can guide the development of new cancer treatments.
